Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP plus GLP-1 for glucose lowering in critically ill patients
ACTRN12611000735954Phase 2Completed
- Sponsor
- Adam Deane
- Start
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of glucose-dependent insulinotropic polypeptide[1-42] and Glucagon-like peptide 1 in hyperglycemia (2 arms), sponsored by Adam Deane. Primary endpoint: Blood glucose area under the curve. Started Aug 2011; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]Glucagon-like peptide 1
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on ACTRN12611000735954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000735954.